Pasithea Therapeutics Corp. - Common Stock (NQ:KTTA)

0.4549 -0.0211 (-4.43%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pasithea Therapeutics Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

A New BioTech Research Race Is Focused On Improving Life For MS Patients ↗

October 27, 2022

When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is...

Via Benzinga

Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive ↗

October 14, 2022

Via Benzinga

Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics

October 13, 2022

From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 12, 2022

Gainers

Via Benzinga

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

October 03, 2022

Learn More about Pasithea Therapeutics by gaining access to the latest research report

Via TheNewswire.com

Pasithea Therapeutics Awarded A Drug Development Research Grant ↗

July 14, 2022

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding --

Via Benzinga

Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028

October 12, 2022

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...

Via FinancialNewsMedia

EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition ↗

October 12, 2022

Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired AlloMek Therapeutics LLC, a privately-held biotechnology company,

Via Benzinga

New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope ↗

October 10, 2022

People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.

Via Benzinga

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

October 03, 2022

By Mark Gilman, Benzinga

Via News Direct

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis ↗

October 03, 2022

Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease.

Via Benzinga

Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022

September 29, 2022

Via Get News

Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors

September 28, 2022

From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC

Via Business Wire

Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics

September 06, 2022

From Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 31, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 30, 2022

Via Benzinga

Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

August 24, 2022

From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC

Via Business Wire

Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029

August 11, 2022

Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...

Via FinancialNewsMedia

EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox ↗

August 11, 2022

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS).

Via Benzinga

Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders ↗

August 08, 2022

An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that...

Via Benzinga

Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting

August 05, 2022

From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 02, 2022

Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is...

Via Benzinga

A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea ↗

July 28, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 22, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 20, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.

Via Benzinga

Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options ↗

July 20, 2022

Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing.

Via Benzinga

Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition ↗

July 18, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development research award following the Company's acquisition of Alpha-5...

Via Benzinga

This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop? ↗

June 27, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated 792 million people around the world...

Via Benzinga

Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5

June 23, 2022

From Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC

Via Business Wire

Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026

June 22, 2022

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...

Via FinancialNewsMedia

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.